13.05.2016 • NewsElaine BurridgePVCCovestro

Ercros Expands Chloralkali Capacity

Spanish chemical company Ercros is spending nearly €54 million to expand membrane chlorine capacity and replace its older mercury cell production. Between 2016 and 2017, Ercros will raise chlorine membrane capacity at Vilaseca, Spain, by 30,000 t/y and also increase capacity for sodium hypochlorite and hydrochloric acid. At the same time, a new plant with a chlorine capacity of 15,000 t/y will be constructed at Sabinanigo.

The company will also improve power reliability at Vilaseca and replace and update the existing caustic soda concentration unit and one PVC reactor. A longer term plan for the period 2018-2020 involves the expansion of trichloroisocyanuric acid (TCCA) capacity at Sabinanigo in addition to increasing production of pentaerythritol and molding compounds at Tortosa and Cerdanyola.

Ercros announced a major cutback in chloralkali capacity in January 2016 as a result of Covestro’s intention to close its MDI plant in Tarragona, Spain, by the end of 2017. Covestro is the largest consumer of chlorine from the Vilaseca plant. The new membrane production will partially replace the reductions outlined at that time.

“The new Ercros that will emerge will have a more balanced portfolio of customer-oriented products with higher added value,” Ercros said in a statement. It added that reduced dependence on electricity and chlorine-related products would reduce the current cyclicality of its EBITDA.

The investments will be 78% financed by cash flow and 22% by debt. Under EU legislation, mercury-based chloralkali production will be banned from November 2017.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.